Total Visits

Views
Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The26

Select a period of time:

Views

Views
January 20250
February 20251
March 202515
April 20252
May 20250
June 20250
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
Germany1
Spain1
United States1
 

Top cities views

Views
Council Bluffs1